SEATTLE--(BUSINESS WIRE)--Adaptive Biotechnologies, the leader in combining next-generation sequencing and expert bioinformatics to profile T-cell and B-cell receptors of the adaptive immune system, and its collaborators from academic institutions around the world will share data further demonstrating the validity and prognostic value of the clonoSEQ® Process for minimal residual disease (MRD) assessment in lymphoid cancers in three oral and eight poster presentations, encompassing six different blood cancer subtypes, at the American Society of Hematology (ASH) Annual Meeting, December 5-8, 2015 in Orlando, FL.
“The clonoSEQ Process provides an ultra-sensitive, standardized method for determining treatment response and predicting outcomes in people with lymphoid cancers,” said Tom Willis, Ph.D., Senior Vice President and General Manager, Diagnostic Products, Adaptive Biotechnologies. “This data demonstrates the breadth of our technology’s applicability, from predicting which patients are most at risk of relapse to guiding treatment after stem cell transplant to providing a reliable surrogate endpoint for use in clinical trials.”
Representatives from Adaptive Biotechnologies will be exhibiting at ASH booth #247 to answer questions about its immunosequencing technology and the clonoSEQ Process, as well as its immunoSEQ® Assays for research use only.
The schedule for Adaptive’s oral presentations is as follows:
Presenter: Nikhil Munshi (Dana-Farber Cancer Institute)
Session:
Myeloma: Biology and Pathophysiology, excluding Therapy: Revealing
Subclonal Heterogeneity in Multiple Myeloma
Presentation Time:
Saturday, December 5, 2015, 8:00 a.m. ET
Location: Tangerine 1 (WF1
| Orange County Convention Center)
Presenter: Hervé Avet-Loiseau (University Hospital Toulouse)
Session:
Myeloma: Therapy, excluding Transplantation: Amyloidosis and Related
Plasma Cell Disorders
Presentation Time: Sunday, December 6, 2015,
8:30 a.m. ET
Location: Tangerine 2 (WF2 | Orange County Convention
Center)
Presenter: Robert Chen (City of Hope)
Session: Clinical Autologous
Transplantation (Results II)
Presentation Time: Monday, December 7,
2015, 7:15 a.m. ET
Location: W224CDGH (Orange County Convention
Center)
The schedule for Adaptive’s poster presentations is as follows:
Saturday, December 5, 2015, 5:30 p.m. – 7:30 p.m. ET
Session: Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models (Poster I)
Session: Acute Lymphoblastic Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis (Poster I)
Session: Myeloma: Biology and Pathophysiology, excluding Therapy (Poster I)
- Abstract No. 1782: A Comparison of Minimal Residual Disease Detection Among ASO-PCR, Dd-PCR and Deep-Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation
- Abstract No. 1788: Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation
Sunday, December 6, 2015, 6:00 p.m. – 8:00 p.m. ET
Session: Non-Hodgkin Lymphoma: Biology, excluding Therapy (Poster II)
Session: Myeloma: Biology and Pathophysiology, excluding Therapy (Poster II)
Session: Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence (Poster II)
Monday, December 7, 2015, 6:00 p.m. – 8:00 p.m. ET
Session: Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence (Poster III)
About Minimal Residual Disease
Minimal residual disease (MRD) refers to cancer cells that may remain in the body of a person with lymphoid cancer after treatment. These cells are present at levels undetectable by traditional microscopic examination (also called morphologic examination) of blood, bone marrow or a lymph node biopsy. Sensitive molecular technologies, such as the next-generation sequencing utilized by the Adaptive Biotechnologies clonoSEQ MRD Test, are needed for reliable detection of very low levels of MRD.
About the clonoSEQ® Process
The Adaptive Biotechnologies clonoSEQ Process enables physicians to utilize sequencing-based minimal residual disease (MRD) detection as an aid to clinical decision making for patients with lymphoid cancers (blood cancers). With its ability to detect cancer cells at a level as low as one per one million white blood cells, the clonoSEQ MRD Test is one to two orders of magnitude more sensitive than other methods of MRD detection, such as ASO-PCR and flow cytometry. The clonoSEQ Process was previously marketed as the ClonoSIGHT™ process by Sequenta, Inc., which was acquired by Adaptive Biotechnologies in January 2015.
MRD detection and quantification using the clonoSEQ Process involves two steps that are easily integrated into patient care. In the first step, the clonoSEQ ID Test, cancer cell DNA sequences are identified in a diagnostic sample. In the second step, the clonoSEQ MRD Test, follow-up samples are screened for the previously identified sequences in order to detect residual disease. ClonoSEQ test results are generated in seven days using the company’s CLIA-certified, CAP-accredited laboratory. These results are provided to the ordering physician in a simple, actionable report that shows a patient’s MRD status and level, as well as MRD trends over time via a secure online portal.
About immunoSEQ® Assays
Adaptive helps researchers make discoveries in oncology, autoimmune disorders and infectious diseases by offering fee-for-service access to its proprietary immune profiling sequencing technology under the immunoSEQ brand name. The immunoSEQ Kit for research use only is also available to facilitate the integration of immunosequencing into research centers. The immunoSEQ Assay is not for use in diagnostic procedures.
About Adaptive Biotechnologies
Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.
